EBF
EBF
EBF
European
Bioanalysis
Forum


EBF vzw is the registered non-profit organisation of the European Bioanalysis Forum

 

2021 – EBF Cyberconnect Events:

Program of EBF Focus Workshop  “Spotlight on (LBA/CBA & Automation) TECHNOLOGY” 20-21 May 2021

PDF renditions of the powerpoint presentations given at the Focus Workshop can be viewed and downloaded from this page. The program itself can be viewed and downloaded by clicking here

Day 1 (times are CEST)
12:30 12:45 Coming online
12:45 13:00 Getting started – Welcome
Philip Timmerman – EBF
13:00 14:30 Session 1: Ligand binding assay technological innovation
13:00 13:10 Introduction to the session by the session chair (Robert Nelson, Covance)
13:10 13:30 Gregor Jordan, F. Hoffmann La Roche
Experience in the use of S-PX imaging and analysis system for sensitive target engagement analysis
13:30 13:50 Christoph Bock, Abbvie
Development of a high sensitivity, single-molecule based ligand binding assay for the detection of biomolecules in a regulated bioanalysis lab – Opportunities, Challenges and Limitations
13:50 14:10 John Chappell, Gyros
Determining Binding Affinity and Kinetics using solution based Ligand binding assays
14:10 14:30 Q&A
Including introduction to session 2 and the round tables
15:00 16:50 Session 2: Functional assays becoming ready for the toolbox of the regulated BA lab
15:00 15:10 SHORT recap of introduction into the session 2 & round tables by session chair (Anna Laurén, Novo Nordisk)
15:10 15:30 Henko Tadema, PRA-HS
Flow cytometry: The pivotal use of flow cytometry in cell therapy development
15:30 15:50 Sion Lewis, UCB Pharma
Flow cytometry: Evolution of the flow lab into the Bioanalytical world
15:50 16:10 Julian J. Freen-van Heeren, Sanquin
Proof of principle for the use of the T cell ELIspot in clinical trial settings
16:10 16:30 Chiara Cazzin, on behalf of EBF
Considerations for the context of use of qPCR application and validation in the BA laboratory”
16:30 16:50 Jessica Zheng Wang, AstraZeneca – Not released for publication (not released for publication)
Development of a mechanism of action reflective and robust potency assay for a therapeutic antibody against alpha toxin using rabbit erythrocytes
16:50 17:00 Logistic break – break into small e-tables/rooms for Interactive round table discussions
17:00 18:15 Session 2: Interactive round tables
Theme: Who will grab “session-2  technologies”?  and what makes sense or doesn’t from a regulatory perspective….
Outcome will be presented on day 2 and is  input for the closing panel discussion
18:15 Close breakout rooms
End of day 1 in plenary “see you tomorrow”
Zoom session stays open to allow continued session or 1/1 interacttions
19:00 Zoom closes
Day 2 (times are CEST)
12:45 13:00 Coming online
13:00 14:40 Session 3: Business Strategies driving Automation or Automation driving Business Strategies?
Session chair: Johannes Stanta, Freeline Therapeutics
13:00 13:20 Johannes Stanta, on behalf of the EBF (and session chair) –  – Not released for publication (not released for publication)
Blue Sky
13:20 13:40 John Smeraglia, UCB Pharma
Role of automation in maximizing portfolio value – the future is now.
13:40 14:00 Nils Boehm, Abbvie
Automation: Impact on operational workflows and information management
14:00 14:20 Katharina Lang, Novo Nordisk
Fully paperless or less paper? A journey towards the paperless lab
14:20 14:40 Cecilia Arfvidsson, on behalf of the EBF
Automation and the DI challenges
14:40 15:00 Break
15:00 16:40 Session 4 – Overcoming challenges – Automation solutions delivering value (incl. pandemic inspired solutions)
Session chair: Matthew Barfield, F. Hoffmann – La Roche
15:00 15:20 Animesh Shukla, AstraZeneca
Benefits, Challenges and Solutions for Setting up Automation in a Regulated Lab: A Case Study
15:20 15:40 Scott Summerfield, GlaxoSmithKline
Transitioning to an ‘automation-first’ culture in Bioanalysis – our learnings from the last 3 year
15:40 16:00 Steffan Svejgaard Petersen, Novo Nordisk
How high-throughput COVID-19 analysis can shape the future of our laboratory automation
16:00 16:20 Michael Gröschl, Celerion
Lab automation in pandemic times – how can robots ensure lab staff`s health and safety?
16:20 16:40 Q&A  and discussion
16:40 17:00 Short break
17:00 18:00 Session 2 round table recap and close out panel discussion
Feedback from day-1 round table
Panel discussion and recommended next steps
18:00 Adjourn
Meeting ends
Zoom session stays open to allow continued session or 1/1 interacttions
19:00 Zoom closes

 

 

Organising Committee: : Matthew Barfield (Roche), Anna Laurén (NovoNordisk), Robert Nelson (Covance), Johannes Stanta (Freeline Therapeutics) and Philip Timmerman (EBF)